# A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combi

Source: https://onco.cc/trials/nct04077723/  
OnCo record `nct04077723` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of Englumafusp alfa, Obinutuzumab, Glofitamab in non-hodgkin lymphoma, run by Hoffmann-La Roche, active and no longer recruiting.

## Summary

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma is a phase 1/2 interventional study registered as NCT04077723 by Hoffmann-La Roche, with 498 participants planned, started 2019-08-13 and due to reach its primary completion in 2027-03-31. Interventions recorded: Englumafusp alfa, Obinutuzumab, Glofitamab, Tocilizumab. Conditions listed: Lymphoma, Non-Hodgkin. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: ctgov-ingest
- Registry id: NCT04077723
- Phase: 1/2
- Setting: An Open-Label, Phase I/II Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of Englumafusp Alfa (RO7227166, A CD19 Targeted 4-1BB Ligand) in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma
- Sponsor: Hoffmann-La Roche
- Enrolled: 498

## Sources

- ClinicalTrials.gov NCT04077723: https://clinicaltrials.gov/study/NCT04077723

## Connected records

- cancers: [Non-Hodgkin lymphoma (all types)](https://onco.cc/cancers/non-hodgkin-lymphoma/)
- drugs: [Englumafusp alfa](https://onco.cc/drugs/englumafusp-alfa/), [Glofitamab](https://onco.cc/drugs/glofitamab/), [Obinutuzumab](https://onco.cc/drugs/obinutuzumab/), [Tocilizumab](https://onco.cc/drugs/tocilizumab/)
- companies: [Roche / Genentech](https://onco.cc/companies/roche-genentech/)

---
JSON: https://onco.cc/api/v1/entities/nct04077723.json